Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

National Cancer Institute

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

AstraZeneca wins EU approvals for Zurampic and Brilique

Its gout drug receives a licence and antiplatelet therapy gains a new indication

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

- PMLiVE

Mismanagement of Cancer Drugs Fund “unacceptable”

Influential committee of MPs finds the government still unable to assess CDF's patient benefit

Harnessing complexity

Companion diagnostics in oncology

- PMLiVE

AstraZeneca wins European approval for Tagrisso

The first-in-class lung cancer treatment receives a conditional licence

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links